New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
21 nov. 2022 07h30 HE
|
Adaptive Biotechnologies
>95% of patients who had an MRD test describe that MRD testing helped inform treatment decisions or brought comfort in their treatment journey85% of surveyed patients have heard of MRD testing, yet...
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
03 nov. 2022 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
11 oct. 2022 08h05 HE
|
Adaptive Biotechnologies
SEATTLE, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
05 oct. 2022 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system...
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
12 sept. 2022 08h30 HE
|
Adaptive Biotechnologies
SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system...
Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference
02 sept. 2022 08h00 HE
|
Adaptive Biotechnologies
SEATTLE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results
03 août 2022 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma
28 juil. 2022 07h30 HE
|
Adaptive Biotechnologies
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022
08 juil. 2022 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, July 08, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease
15 juin 2022 07h30 HE
|
Adaptive Biotechnologies
SEATTLE, June 15, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...